- Peptide Menu
- Custom Peptides
- Peptide News
- Peptide News Archive
- Peptide Suppliers
- Peptide Books
- Peptide Journals
- Peptide Synthesizers
- Peptide Resources
- Peptide Forum
- Custom Peptide Synthesis
- Peptide Synthesis
- Contact Us
- Peptide Techniques
- Peptide Protocols
- Peptide Bioinformatics
Sponsored
Peptide Research News
Peptide Research News - Galena Presents Data From Phase 1/2 Clinical Trial Of NeuVax - Quick Facts - RTT News
home > news Galena Presents Data From Phase 1/2 Clinical Trial Of NeuVax - Quick Facts - RTT News
Galena Presents Data From Phase 1/2 Clinical Trial Of NeuVax - Quick Facts - RTT News
 |
 |
 |
Galena Presents Data From Phase 1/2 Clinical Trial Of NeuVax - Quick Facts RTT News The Phase 1/2 clinical trials assessed the NeuVax (E75) vaccine, an HLA A2/A3 restricted HER2/neu (HER2) peptide, mixed with GM-CSF. The trials evaluated a combined 187 patients and have completed a median 60-months of follow-up, with the final ... Galena Biopharma Presents NeuVax Phase 1/2 Boosters Improve Disease-Free ... |
Click Here to read the entire article...